Contineum, J&J's depression drug fails to meet mid-stage trial goal

Contineum Therapeutics' experimental depression drug, developed with Johnson & Johnson, failed to meet the primary endpoint in a mid-stage clinical study. The setback materially weakens the program's development outlook and is likely to pressure Contineum shares, while having a limited impact on Johnson & Johnson.